Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer

紫杉烷 医学 艾瑞布林 蒽环类 肿瘤科 卡铂 转移性乳腺癌 内科学 卡培他滨 三阴性乳腺癌 乳腺癌 化疗 癌症 顺铂 结直肠癌
作者
Stephanie B. Wheeler,Jason Rotter,Anagha Gogate,Katherine E. Reeder‐Hayes,Sarah W. Drier,Donatus U. Ekwueme,Temeika L. Fairley,Gabrielle B. Rocque,Justin G. Trogdon
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (1): 32-42 被引量:5
标识
DOI:10.1200/jco.21.02473
摘要

PURPOSE Treatments for endocrine-refractory or triple-negative metastatic breast cancer (mBC) are modestly effective at prolonging life and improving quality of life but can be extremely expensive. Given these tradeoffs in quality of life and cost, the optimal choice of treatment sequencing is unclear. Cost-effectiveness analysis can explicitly quantify such tradeoffs, enabling more informed decision making. Our objective was to estimate the societal cost-effectiveness of different therapeutic alternatives in the first- to third-line sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative mBC. METHODS Using three dynamic microsimulation models of 10,000 patients each, three cohorts were simulated, based upon prior chemotherapy exposure: (1) unexposed to either taxane or anthracycline, (2) taxane- and anthracycline-exposed, and (3) taxane-exposed/anthracycline-naive. We focused on the following single-agent chemotherapy regimens as reasonable and commonly used options in the first three lines of therapy for each cohort, based upon feedback from oncologists treating endocrine-refractory or triple-negative mBC: (1) for taxane- and anthracycline-unexposed patients, paclitaxel, capecitabine (CAPE), or pegylated liposomal doxorubicin; (2) for taxane- and anthracycline-exposed patients, Eribulin, CAPE, or carboplatin; and (3) for taxane-exposed/anthracycline-naive patients, pegylated liposomal doxorubicin, CAPE, or Eribulin. RESULTS In each cohort, accumulated quality-adjusted life-years were similar between regimens, but total societal costs varied considerably. Sequences beginning first-line treatment with paclitaxel, carboplatin, and CAPE, respectively, for cohorts 1, 2, and 3, had lower costs and similar or slightly better outcomes compared with alternative options. CONCLUSION In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
学好久完成签到 ,获得积分10
1秒前
a24017完成签到,获得积分10
4秒前
YG完成签到,获得积分10
5秒前
yue完成签到,获得积分10
9秒前
淼队完成签到,获得积分10
10秒前
10秒前
落叶解三秋完成签到,获得积分10
11秒前
Crystal完成签到 ,获得积分10
14秒前
小小酥完成签到,获得积分10
14秒前
等待蚂蚁完成签到 ,获得积分10
15秒前
zgt01发布了新的文献求助10
15秒前
心心完成签到 ,获得积分10
16秒前
123完成签到,获得积分10
17秒前
温超完成签到,获得积分10
17秒前
量子星尘发布了新的文献求助10
17秒前
18秒前
19秒前
Menta1y完成签到,获得积分10
19秒前
czzlancer完成签到,获得积分10
20秒前
汶溢完成签到,获得积分10
20秒前
xsss完成签到,获得积分10
21秒前
TAN完成签到,获得积分10
21秒前
通通通发布了新的文献求助10
22秒前
liudw完成签到,获得积分10
22秒前
丹丹子完成签到 ,获得积分10
23秒前
时光完成签到,获得积分10
23秒前
24秒前
充电宝应助vsvsgo采纳,获得10
26秒前
123完成签到 ,获得积分10
28秒前
Ammr完成签到 ,获得积分10
28秒前
无限的依波完成签到,获得积分10
28秒前
姽婳wy发布了新的文献求助10
29秒前
lemon完成签到,获得积分10
29秒前
传奇3应助duckspy采纳,获得30
30秒前
陈木木完成签到,获得积分10
31秒前
可可西里完成签到,获得积分10
32秒前
奋斗蜗牛完成签到,获得积分10
32秒前
CipherSage应助眼睛大的擎苍采纳,获得10
32秒前
打打应助小小酥采纳,获得10
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022